Alpha Teknova Stock Price, News & Analysis

Teknova (Nasdaq: TKNO), a producer of critical reagents for therapies, vaccines, and molecular diagnostics, has scheduled its Q2 2025 financial results announcement for August 7, 2025, after market close.

The company will host a conference call and webcast at 5 p.m. Eastern Time on the same day. Investors can access the webcast through Teknova's Investor Relations website, and participants wanting to join the call need to register to receive dial-in information. A replay will be available approximately two hours after the event.

Teknova (NASDAQ: TKNO) reported its Q1 2025 financial results, showing total revenue of $9.8 million, a 5% increase from Q1 2024. The company's Lab Essentials segment grew 12% to $8.1 million, while Clinical Solutions revenue decreased 32% to $1.2 million. Gross margin improved to 30.7% from 23.8% year-over-year. The company reported a net loss of $4.6 million ($0.09 per share), compared to $8.1 million loss in Q1 2024. Notably, Teknova entered into a collaboration with Pluristyx to become the exclusive manufacturer and distributor of the PluriFreeze™ cryopreservation system in the US and Canada. The company maintained its 2025 revenue guidance of $39-42 million and expects free cash outflow of less than $12 million.

Teknova (Nasdaq: TKNO), a leading producer of critical reagents for therapy, vaccine, and molecular diagnostics development, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close. The company will host a webcast and conference call at 5 p.m. Eastern Time on the same day. Interested participants can access the webcast through Teknova's Investor Relations section and must register to receive a unique PIN for dial-in access. A replay will be available on the company's website approximately two hours after the event.

Teknova (Nasdaq: TKNO) and Pluristyx have launched the PluriFreeze™ cryopreservation system, now exclusively available through Teknova in the US and Canada. The innovative product line includes two key components: PluriFreeze Base, a cellular wash mimicking intracellular space, and PluriFreeze PF10, a low viscosity freezing medium with 10% DMSO.

The system is entirely synthetic and animal-origin-free, designed to streamline the development and commercialization of allogeneic cell therapies. Research-grade products are priced at $240 per 100 mL for PluriFreeze Base and $260 per 100 mL for PluriFreeze PF10, with GMP-grade versions available upon request. Free product samples are offered through March 21, 2025.

Teknova (Nasdaq: TKNO) and Pluristyx have announced a strategic collaboration where Teknova will become the exclusive manufacturer and distributor of Pluristyx's PluriFreeze™ product line in the United States and Canada. The PluriFreeze system is a novel cryopreservative and cell wash media system designed for next-generation allogeneic cell therapies.

The system consists of two key components: PluriFreeze Base, a protective wash mimicking intracellular space, and PluriFreeze PF10, a low viscosity freezing medium with 10% DMSO. The entirely synthetic and animal-origin-free system aims to streamline the scale-up process for companies developing allogeneic cell therapies.

Further details about the collaboration, including pricing and availability, will be announced at the BioProcess International West conference in San Diego, starting March 19, 2025.

Teknova (TKNO) reported its Q4 and full-year 2024 financial results, with total revenue reaching $37.7 million for FY2024, up 3% year-over-year. Q4 2024 revenue was $9.3 million, an 18% increase from Q4 2023.

Key highlights include:

• Clinical Solutions revenue grew 110% in Q4 2024 to $1.9 million
• 41% annual growth in Clinical Solutions customers
• Lab Essentials revenue reached $6.8 million in Q4, up 2%
• Year-end cash position of $30.4 million with $12.1 million in gross debt

The company improved its operational efficiency and reduced cash burn, with free cash outflow decreasing to $13.5 million in 2024 from $26.7 million in 2023. For 2025, Teknova provided revenue guidance of $39-42 million with expected free cash outflow below $12 million.

Teknova (Nasdaq: TKNO), a producer of critical reagents for therapy, vaccine, and molecular diagnostics development, has scheduled its fourth quarter and full year 2024 financial results announcement for March 4, 2025, after market close. The company will host a webcast and conference call at 5 p.m. Eastern Time on the same day. Investors can access the webcast through Teknova's Investor Relations website section, and participants requiring dial-in information need to register to receive a unique PIN number.

Teknova (TKNO) reported Q3 2024 revenue of $9.6 million, up 17% year-over-year. The company reaffirmed its 2024 revenue guidance of $35-38 million while lowering its free cash outflow outlook from $18 million to $16 million. Q3 Lab Essentials revenue remained stable at $7.2 million, while Clinical Solutions revenue grew 229% to $2.0 million. The company recorded a $2.8 million non-recurring charge related to inventory write-downs, resulting in a gross margin of 0.9%. Excluding this charge, gross margin would have been 29.8%. Total cash and short-term investments stood at $31.7 million with gross debt of $12.1 million.

Alpha Teknova (Nasdaq: TKNO), a producer of critical reagents for therapy, vaccine, and molecular diagnostics development, has announced it will release its third quarter 2024 financial results on November 7, 2024, after market close. The company will host a webcast and conference call at 5:30 p.m. Eastern Time on the same day. Investors can access the webcast through Teknova's Investor Relations website section, and participants need to register to receive dial-in information.